Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Phase 2
40 patients
Find a stroke -not for profit - to help fund
Biometric of neuronal cell growth
and patient improvement ..
Means the pathway is multi billions..
Chris just tell us how you will reward
Agnpf shareholders with success.
Thx
The perhaps part should be spelled out.
Look.. I believ this is a brilliant move with DMT ..
really I do..
I bet I can do a Google in DMT and feel confident that DMT is going to kick some serious CNS malfunctions..
What do we benefit? Owning 50% of a billion dollar co does NOT mean you are worth $600 million..
It doesn’t..
Spell it out .. thx
Remember that the DMT Phase 1 was to determine "sub psychedelic dose levels". AGN had also paid for specific neuro marker tests that should help prove ' MOU/ proof of concept' for the upcoming Phase 2 CT, which is/has been planned now.
I sure hope that phase 2 data from the Ifenprodil CT will help find a buyer as that data is as strong as any drug's for IPF/CC. This should be enough to finance the next steps for DMT, possible even the whols Phase 2 CT. I bet this is 'of course' the main focus for Mr Monroue.
The peer data from DMT should also be released soon.
As 60% owners of AGN-Neuro we are financing all this and at the least will see proportional benefits, maybe even the dividends you mentioned. JMHO.
...GLTA...
Good discussion by tcm and McM.
100% agree with you both.
It’s looking pretty grim, but I’m always down for a last minute Hail Mary.
I’m not convinced Moreau won’t screw shareholders in the end, but who knows… maybe Algernon will surprise us all.
Ifenprodil seems to have great potential.
The fact that Ivermectin is now suddenly being widely accepted as a treatment for COVID certainly makes you question everything within the realm of pharma.
Why wouldn’t you do no psych dose to grow neurons?
I think dementia patients will be talking this treatment .
The bigger factor is
many Canadian companies treat
their companies like club Canada..
They make sure Canadians win
and really everyone else is a second class.
I get that for protecting ownership in Canadian hands.. us should do a better job.
Personally I would like to see
a forward plan..
Of what happens WHEN we are successful?
Do we get dividends?
We own 60% of algernon Neuro but what does that mean?
I think this is a winner..
but have seen winners be losers for
common shareholders and not leadership..
So I love the product
Love the opportunity
Like Chris and his leadership..
Could absolutely go much deeper investment wise if I understood
How all investors will win when this becomes a blockbuster drug..
Why wouldn’t the neuroscience people just invest in algernon?
Is algernon going to dividend the 60% of neuroscience to shareholders?
Holding companies May languish for very long periods of time
Stroke is like cancer, IMO. There will be plenty of folks willing to try anything to help. Most cancer drugs are $10k a treatment / dose ( Ketruda/Optivo) and some were $70k a dose (Yeravoy).
So basically I see the stroke treatment is doctor supervision costs and the DMT probably will be much less per dose. Certainly a large patient population that needs something.
Sure hope they can sell their/our work and rights from the Ifenprodil Clinical Trials, CC/IPF, to help finance this. Seemed a viable alternative to the other much more expensive drugs with about equal results...
...GLTA...
Don’t think they’re going to make it at this point … who’s going to give them the right to Ginny pig a patient that just had a stroke…not making since imo
Outstanding: 15,775,757 posted for August 8, 2023
Monthly 5th Report
https://webfiles.thecse.com/7._Algernon_-_CSE_Form_7_-_July_2023.pdf?zwGrUHYlGcXfmUGKGAi9jEkDIHCkOide
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-Announces-40-Patient-Phase-2-Psychedelic-Drug-DMT-Stroke-Study?id=410020
13. SUBSEQUENT EVENTS
Subsequent to May 31, 2023
On July 26, 2023, the Company issued to Maxim Group LLC (“Maxim”) 200,000 common shares at a deemed issue price of $0.22, being the closing price of the common shares on the CSE on July 13, 2023, as initial compensation for entering into an engagement letter (the “Engagement Letter”) pursuant to which Maxim will provide financial advisory and investment banking services, and assist in identifying and evaluating potential M&A and strategic opportunities, including the potential spin-off of the Company's Ifenprodil chronic cough research program. In connection with entering into the Engagement Letter, the Company may be obligated to issue up to an additional 200,000 Common Shares to Maxim in certain circumstances. The Company may also be obligated to pay Maxim a success fee upon the consummation of a successful transaction.
On July 27, 2023, the Company closed a non-brokered private placement for gross proceeds of $205,000 (the “Offering”) of units (the “July 2023 Units”) at an issue price of $0.20 per July 2023 Unit. Each July 2023 Unit will consist of one common share in the capital of the Company and one common share purchase warrant (a “July 2023 Warrant”). Each July 2023 Warrant will entitle the holder to acquire one common share (a “July 2023 Warrant Share”) at an exercise price of $0.25 per July 2023 Warrant Share for a period of 2 years from the date of issuance (the “Expiry Date”), subject to acceleration of the Expiry Date as described below.
The July 2023 Warrants are subject to accelerated expiry in the event the volume weighted average trading price of the common shares exceeds $0.50 for 20 consecutive trading days, the Company may, within 10 business days of the occurrence of such event, deliver a notice to the holders of the July 2023 Warrants accelerating the Expiry Date of the July 2023 Warrants to a date that is not less than 30 days following the date of such notice and the issuance of a press release by the Company announcing the acceleration notice (the “Accelerated Exercise Period”). Any unexercised July 2023 Warrants shall automatically expire at the end of the Accelerated Exercise Period. The Company will use the proceeds of the private placement for working capital purposes.
JMO
It appears their dumping what they can for cash to stay alive - $400,000 cash on hand May 31st, 2023 and now $205,000 for shares sold in placement makes $605,000 and burn rate a quarter is up to $1M now - All paid with more shares to insiders or Brokers doing placements with more shares
Here’s the latest MD&A
https://webfiles.thecse.com/Algernon_-_Financial_Statements_-_May_31_2023.pdf?3BDnofPUaIMafoRlE30llhlwsGG5Rhat
Condensed Interim Consolidated Financial Statements
https://webfiles.thecse.com/Algernon_-_Financial_Statements_-_May_31_2023.pdf?3BDnofPUaIMafoRlE30llhlwsGG5Rhat=
Issued and outstanding following issuance: 15,575,757
Some reason Filed again yesterday
https://webfiles.thecse.com/Algernon_CSE_Form_9_-_July_2023_PP_-_Final.pdf?AWE_cWufzfHhRkPjfoS4JZ5UXeAzLh9h=
Issued and outstanding following issuance: 15,575,757
https://webfiles.thecse.com/Algernon_CSE_Form_9_-_July_2023_1.pdf?1MYTNb8DX21yPvQjs9PGg0ww0a8t8._6;
Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
That didn’t take long and these after Shareholders just gave $0.25 $AGN or $0.18 $AGNPF for shares the held if used the Right, these are $0.20 $AGN - $0.1513 $AGNPF
Bet the Warrants are even less then Shareholders that bought the Rights cost of their Warrants
1M shares $205,000 CAD or $155,400 USD
Let’s not forget the 200,000 shares thrown to Broker so 1.2M added to the 14,550,757 Outstanding or now 15,750,757 there about’s
https://webfiles.thecse.com/AGNnr071423.pdf?8MkGXiMSCGYehenUVxbhFTHJyEJDSOi_
Just what I thought and Warrants are $0.25 where shareholders Warrants are $0.52
Outstanding: 14,550,757 posted July 7, 2023
Monthly 5th Report
https://webfiles.thecse.com/6._Algernon_-_CSE_Form_7_-_June_2023.pdf?cQZO818.1IAt0DJJNp9zarUmr1A_ttLX
Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Engages-Maxim-Group-to-Explore-Spin-Off-of-its-Ifenprodil-Phase-2-Chronic-Cough-Drug-Developmen?id=405608
hummmmm… market makers controlling the share price… FULL STOP… just the facts… egg Zack lee… FULL STOP… bro…
GO Algernon! GLTA
:)
hum… no pop in buys after cough conference speaks for itself … maybe a penny in one year?
Good Video - Here’s a $AGNPF & Jacky Smith News clip
https://www.globenewswire.com/en/news-release/2020/02/07/1981672/0/en/Algernon-Pharmaceuticals-Appoints-Professor-of-Respiratory-Medicine-Dr-Jacky-Smith-to-Its-Medical-and-Scientific-Advisory-Board.html
Dr jacki Smith gives the final wrap up. Isnt she an advisor for AGN?
Anyway nice to see our drug mentioned with the other big names. Didnt Ifenprodil beat Gabapixen in a murine test by +40%?
Play the whole video, "therapeutic landscape" ( or)16:30+
...GLTA...
https://www.americancoughconference.com/#:~:text=The%20American%20Cough%20Conference%20is%20the%20world%27s%20leading,the%20generous%20support%20of%20our%20sponsors%20and%20exhibitors.
Cheers to that …bro!!
FULL STOP :)
must be some good news ;)
What’s up with this
https://sedar-filings-backup.thecse.com/00037722/2306191408040550.pdf
Form 62-103F3 - AlphaNorth Asset Management (the “Offeror”)
Yes, it doesn’t take much to move this stock a couple cents. Hoping for a good Phase 1 and continued interest also!
GLTA!
After the 80k of buys someone dropped the pps 5% with a one hundred share buy. I had a hard time getting 5k yesterday @ .1825, as I try to support the pps occasionally. I sure dont understand that the ask was .185 and this 100 shares went @ .17. I dont understand a lot of stuff, LOL...
I hope they expedite the readout of the Stage 1 asap and we see some actual continued interest. Could happen...
...GLTA...
Whoa Bro!… $14,922 td…. time for da big time… FULL STOP… just the facts… egg Zack Lee… FULL STOP…. Bro…
:)
Outstanding: 14,550,757 for June 5, 2023 Monthly Report
Monthly 5th Report
https://webfiles.thecse.com/5._Algernon_-_CSE_Form_7_-_May_2023.pdf?Ghag5daIWQXtzfM02z6tAHLE0LvW664R
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-to-Present-Phase-2-Ifenprodil-Cough-Data-at-the-2023-American-Cough-Conference?id=403381
CEO Discusses Successful High Dose Completion in DMT Phase 1 Trial for Stroke and TBI
Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Studies
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-Announces-Successful-Completion-of-Highest-Planned-Single-Dose-in-DMT-Phase-1-Trial-Accelerates-Pl?id=403236
Proactive Investors CEO Interview - Algernon Receives Notice of Allowance for Patent to Treat Chronic Kidney Disease in Japan
Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Receives-Notice-of-Allowance-from-the-Japanese-Patent-Office-for-Repirinast-and-the-Treatment-o?id=402759
Me too bro… been a long road… Go Algernon!!… FULL STOP… just the facts… egg-Zack-lee… Bro!!!
:)
Moreau…say’s takes less time to introduce re-purposed drugs than to bring new drug to market which could take years lol …forgetting how many years I have been here now… food for thought.
Yo bro’s… have a great weekend…. Go Algernon!!!…. Just the facts… FULL STOP…. Bro…
:) GLTA!!
Yo bro… I got this one too ;) …. BIG DAY!…. $6,031 yd… Yowza!… FULL STOP… Just the facts…. Bro…
:)
Yo bro…. I got this one… $788.7 td :) … FULL STOP…. Just the facts… Bro…
:)
Cool… you got it bro…. GO ALGERNON!…. You can do it!!… FULL STOP…. Bro…
:)
Cool…. Big day!… FULL STOP… Bro…
:)
Facts? Yeah...tell me all about them. I'm all ears.
Holla
M$
Cool…. Yeah, I feel ya bro… just facts… FULL STOP…. Carry on BRO…
:)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |